Vir Biotechnology and Gilead Sciences have announced a significant new strategic partnership aimed at accelerating the discovery and development of next-generation cancer therapies. Under the terms of the collaboration and license agreement, the two companies will join forces to engineer novel T-cell engager (TCE) candidates specifically designed to target difficult-to-treat solid tumors.
This high-stakes agreement grants Gilead Sciences an exclusive license to develop and commercialize three dual-masked TCE candidates. These therapies will leverage Vir’s proprietary PRO-XTEN technology, a platform engineered to enhance the efficacy and safety profile of biologic drugs. While Vir will spearhead the discovery, design, and optimization phases of the project, Gilead retains the right to nominate and advance the selected candidates through clinical development.
The financial scope of the deal reflects the high expectations placed on this partnership. Vir Biotechnology is set to receive an initial $135 million in upfront and near-term preclinical milestone payments. Furthermore, the agreement includes performance-based incentives that could see the total value of the deal reach up to $1.74 billion, contingent upon the achievement of specific development, regulatory, and commercial milestones.
To create these high-quality TCEs, Vir plans to integrate its PRO-XTEN platform with its “dAIsY” (data AI structure and antibodY) technology. This combination is designed to allow for rapid, multiparameter optimization, resulting in therapies that offer potent anti-tumor activity while maintaining a wide therapeutic index. By utilizing a “dual-masked” approach, the companies hope to minimize systemic toxicities, a common hurdle in the development of potent cancer immunotherapies, particularly within the challenging landscape of solid tumors.
“We believe TCEs have a powerful role to play to treat cancer,” said Marianne De Backer, President and CEO of Vir Biotechnology. She noted that the collaboration serves as external validation of Vir’s integrated discovery capabilities and underscores the versatility of their technology platforms. “This provides an opportunity to generate multiple differentiated candidates aimed at difficult-to-address solid tumors.”
Gilead Sciences, which has been aggressively expanding its footprint in oncology, views the partnership as a critical step in building out its portfolio of next-generation immunotherapies. Flavius Martin, MD, Executive Vice President of Research at Gilead, emphasized that the collaboration aligns perfectly with the company’s broader strategic focus.
“Together with Vir Biotechnology, we seek to bring meaningful innovative therapeutics to patients,” Martin stated.
For the medical community, this partnership represents a targeted effort to address one of the most persistent areas of high unmet need in oncology. By combining Vir’s protein engineering expertise with Gilead’s extensive clinical development infrastructure, the companies hope to deliver a new class of precise, effective treatments for patients fighting complex solid tumors.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
